Overview

Treatment With hOKT3gamma1(Ala-Ala) in T1DM

Status:
Terminated

Trial end date:
2007-08-01

Target enrollment:

Participant gender:

Summary

This is a phase II study to examine the clinical and immunological effects of humanized FcR non-binding anti-CD3 mAb in participants with Type 1 diabetes mellitus (T1DM), and to develop this therapy to prevent the immune destruction leading to β cell loss.

Phase:

Phase 2

Details

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborator:

Immune Tolerance Network (ITN)